The Blog

Vivodyne opened the world's largest human data center outside San Francisco—a fleet of HIVE robotic labs growing 20 types of human tissue and dosing, monitoring, and tracking hundreds of thousands of experiments in parallel. TechCrunch went inside to see why the causal, human-scale data these tissues generate is the piece AI drug discovery has been missing.

Vivodyne unveils largest human tissue datacenter for drug testing and tissue capability to resolve drug responses previously missed in animal testing.

Fast Company explores how Vivodyne is using AI and lab-grown human tissues to build a new model for drug development. By running experiments on human biology at scale, Vivodyne aims to reduce reliance on animal testing while helping researchers identify drug candidates with a better chance of working in people.

Andrei Georgescu discusses how Vivodyne grows human tissues at massive scale to test thousands of drug candidates without relying on animal models or human trials. He explains how the technology could reduce drug-development failures, support personalized medicine, and advance safer, more effective treatments.

Vivodyne shares news of announcement of largest human datacenter with ETN.

Vivodyne says that eight of the world’s largest pharma companies have paid for early access to the human biological datacenter platform.

Vivodyne, the company making human biology computable at AI scale, today announced the world’s largest human biological datacenter, with 12 robotic HIVE labs.

Nature Biotechnology highlights Vivodyne among the emerging technologies advancing AI-powered, human-relevant drug testing, as the industry moves toward more predictive alternatives to traditional animal models.

Inside Precision Medicine highlights Vivodyne’s approach to combining automated laboratories with artificial intelligence to accelerate drug discovery. By creating a feedback loop between experiments and AI, Vivodyne aims to identify promising drug targets faster and determine which candidates are most likely to succeed.

Fast Company recognizes Vivodyne among 2026’s most innovative biotech companies for its work advancing human-relevant drug development. Vivodyne uses highly automated laboratories and living human tissues representing healthy and diseased states to help predict drug response and reduce reliance on animal studies.

In this Onyx Newsroom interview, Vivodyne CEO Andrei Georgescu shares how the company is building scalable, automated infrastructure to turn complex human tissues into searchable biological data and accelerate preclinical drug discovery.

Vivodyne co-founder and CEO Andrei Georgescu joins Mendelspod to explore the future of drug development beyond animal testing. The conversation examines how Vivodyne’s AI-enabled, lab-grown human tissues could help researchers evaluate drug safety and efficacy using more human-relevant biology.

Vivodyne Co-Founder and CEO Andrei Georgescu joins Great Entrepreneurs with RJ Lumba to discuss how Vivodyne is transforming drug discovery with lab-grown 3D human tissues, scalable robotics, and AI—generating more predictive human data to help bring better therapies to patients faster.

Vivodyne has raised $40 million in new Series A financing to scale its robotics+AI approach to testing on thousands of lab-grown, fully-functional human tissues, and the massive amount of human data they generate. With the new financing, Vivodyne will open a 23,000-square-foot fully robotic laboratory at Genesis Marina in South San Francisco.

Vivodyne, a San Francisco-based startup using lab-grown human tissues to discover and develop drugs, raised $40 million in a Series A led by Khosla Ventures.

Vivodyne could capitalize on the desire for new approaches to preclinical research.

Andrei Georgescu of Vivodyne discusses key advantages of its humanized drug testing platform and the impact of the FDA’s policy shift with Contract Pharma.

In a roadmap to change animal testing requirements for INDs, the U.S. FDA said its new approach will improve drug safety, hasten the evaluation process, and lower costs for companies and patients. It’s another step in a process of changing rules put in place decades ago.

Andrei Georgescu of Vivodyne discusses key advantages of its humanized drug testing platform and the impact of the FDA’s policy shift with Endpoints News.

Firstword Pharma speaks with CEO & Co-Founder Andrei Georgescu about the recent FDA initiative aimed at eliminating the need to test monoclonal antibody therapeutics in animal models. Instead, the agency suggested that animal testing could be replaced with AI modelling or lab-grown human organoids.

Our Co-Founder, Andrei Georgescu, recently took the stage at the Forbes Healthcare Summit to discuss how AI and human organ models are accelerating the future of drug discovery.

In this insightful conversation, our CEO delves into how Vivodyne enables human testing before clinical trials. Our innovative platform has the capacity to cultivate tens of thousands of human tissue models at scale, setting a new standard in the field.

Vivodyne announces the close of $38 million in total seed financing, led by Khosla Ventures, with participation from Kairos Ventures, CS Ventures, MBX Capital, and Bison Ventures.

Vivodyne announces that it has expanded its leadership team with Anthony Bahinski, Ph.D., MBA, FAHA joining as its Chief Biotechnology Officer.

Vivodyne has been named #1 in the list of Fast Company’s World’s Most Innovative “Small but Mighty” Companies for 2022.

Vivodyne is the latest startup from UPenn Bioengineering to raise $4 million in Seed Funding, led by Kairos Ventures